Delisting risk
BJDX · NASDAQ · Medical - Devices

Bluejay Diagnostics (BJDX)

Develops near-patient IL-6 diagnostics for sepsis risk assessment.

$0.8552
Pre-market+0.01 (+1.18%)
At close$0.8452(−0.27%)

Something off on this page? Send us feedback.

Next report
Nov 13, 2026
estimated · in 71 days
EPS estimate
−$3,520.00
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$112.37−$3.37−$1.41−$4.04−$2.37−$1.95−$1.12Pending
Estimate−$144.00−$3,520.00−$3,520.00
Surprise+22.0%+100.0%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$216.1KPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$3,520.00
Aug 2026−$3,520.00−$1.12+100.0%
May 2026−$1.95
Mar 2026−$2.37
Nov 2025−$4.04

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Jul 2022
Apr 2022
Mar 2022
Dec 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 13, 2026−$3,520.00
Aug 12, 2026−$3,520.00−$1.12+100.0%−1.9%
May 13, 2026−$1.95−1.7%
Mar 6, 2026−$2.37+0.5%
Nov 7, 2025−$4.040.0%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 7, 2025
May 13, 2025
Mar 31, 2025
Nov 7, 2024
Aug 14, 2024
May 15, 2024
Mar 28, 2024
Nov 9, 2023
Aug 14, 2023
May 10, 2023
Mar 20, 2023
Nov 9, 2022
Jul 26, 2022
Apr 20, 2022
Mar 10, 2022
Dec 16, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020